PATENT CLAIM ANALYSIS

Application Number: 16255690
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-08
Patent Classification: ["424", "139100"]

Abstract:
Provided are IFN-y-Inducible Regulatory T Cell Convertible Anti-Cancer (IRTCA) antibodies and antigen-binding fragment thereof that bind to an activation-inducible TNFR (AITR) polypeptide. Various in vitro and in vivo methods and compositions related to IRTCA antibodies described herein are also provided. Methods include, for example, changing cytokine secretion from T cells in vivo or in vitro and prevention and/or therapeutic treatment of cancer using an IRTCA antibody or fragment thereof.

Claim (Index 23):
The method of  claim 22 , where in the cancer is selected from a bladder cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, fallopian tube cancer, gall bladder cancer, gastrointestinal cancer, head and neck cancer, hematological cancer, laryngeal cancer, liver cancer, lung cancer, lymphoma, melanoma, mesothelioma, ovarian cancer, primary peritoneal cancer, salivary gland cancer, sarcoma, stomach cancer, thyroid cancer, pancreatic cancer, renal cell carcinoma, glioblastoma, and prostate cancer.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 99.0
- Lexical Diversity: 1.41818
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15863526', '15507012', '14194797', '15495048', '14076214']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7644073617753893
- 35 USC 102 Novelty (BERT): 0.5584800401857201
- Combined Prediction Score: 0.7438146296164224
- Mean Citation Score: 398.371636
- Max Citation Score: 428.79395
- Similarity Product: 320.401234202069

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test